参考文献/References:
[1] Asbury AK,Cornblath DR.Assessment of current diagnostic criteria for Guillain-Barre syndrome[J].Ann Neurol,1990,27(Suppl):S21-24.
[2] Hughes RC.Cornblath DR.Guillain-Barré syndrome[J].Lancet,2005,366(9497):1653-1666.
[3] Van Doorn PA.Ruts L,jacobs BC.clinical features,pathogenesis,and treatment of Guillain-Barré syndrome[J].The Lancet Neurology,2008,7(10):939-950.
[4] Yuki N,Hartung HP.Guillain-Barre syndrome[J].N Engl J Med,2012,366(24):2294-2304.
[5] Griffin JW,Li CY,Ho TW,et al.Guillain-Barre syndrome in northern China.the spectrum of neuropathological changes in clinically defined cases[J].Brain,1995,118(Pt 3):577-595.
[6] Hadden RD,Cornblath DR,Hughes RA,et al.Electrophysiological classification of Guillain-Barre syndrome:clinical associations and outcome.Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group[J].Ann Neurol,1998,44(5):780-788.
[7] Kuwabara S,Yuki N.Axonal Guillain-Barre syndrome: concepts and controversies[J].Lancet Neurol,2013,12(12):1180-1188.
[8] Van Der Meche FG,Van Doorn PA,Meulstee J,et al.Diagnostic and classification criteria for the Guillain-Barre syndrome[J].Eur Neurol,2001,45(3):133-139.
[9] Roodbol J,De Wit M-,Aarsen FK,et al.Long-term outcome of guillain-barre syndrome in children[J].Journal of the Peripheral Nervous System,2011,16(3):S119.
[10] Bernsen RA,De Jager AE,Schmitz PI,et al.Residual physical outcome and daily living 3 to 6 years after Guillain-Barre syndrome[J].Neurology,1999,53(2):409-410.
[11] Appropriate Number of Plasma Exchanges in Guillain-Barre Syndrome.The French cooperative group on plasma exchange in Guillain-Barre syndrome[J].Ann Neurol,1997,41(3):298-306.
[12] Rees JH,Thompson RD,Smeeton NC,et al.Epidemiological study of Guillain-Barre syndrome in South East England[J].J Neurol Neurosurg Psychiatry,1998,64(1):74-77.
[13] Sharshar T,Chevret S,Bourdain F,et al.Early predictors of mechanical ventilation in Guillain-Barre syndrome[J].Crit Care Med,2003,31(1):278-283.
[14] Durand MC,Porcher R,Orlikowski D,et al.Clinical and electrophysiological predictors of respiratory failure in Guillain-Barre syndrome:a prospective study[J].Lancet Neurol,2006,5(12):1021-1028.
[15] Walgaard C,Lingsma HF,Ruts LA,et al.Prediction of respiratory insufficiency in Guillain-Barre syndrome[J].Ann Neurol,2010,67(6):781-787.
[16] Wu X, Li C, Zhang B, et al.Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barre syndrome[J].Critical Care,2015,19(1):1-9.
[17] Nguyen TN,Badjatia N,Malhotra A,et al.Factors predicting extubation success in patients with Guillain-Barre syndrome[J].Neurocrit Care,2006,5(3):230-234.
[18] Zhang HL,Wu J,Ni FM,et al.Axonal variant of Guillain-Barre syndrome associated with campylobacter infection in Bangladesh[J].Neurology,2010,75(2):194-195.
[19] Benamer HT,Bredan A.Guillain-Barre syndrome in Arab countries: a systematic review[J].J Neurol Sci,2014,343(1/2):221-223.
[20] Netto AB,Taly AB,Kulkarni GB,et al.Mortality in mechanically ventilated patients of Guillain Barre Syndrome[J].Ann Indian Acad Neurol,2011,14(4):262-266.
[21] Dhar R,Stitt L,Hahn AF.The morbidity and outcome of patients With Guillain-Barre syndrome admitted to the intensive care unit[J].J Neurol Sci,2008,264(1/2):121-128.
[22] Liou LS,Chung CH,Wu YT,et al.Epidemiology and prognostic factors of inpatient mortality of Guillain-Barre syndrome: A nationwide population study over 14 years in Asian country[J].J Neurol Sci,2016,369:159-164.
[23] Van Den Berg B,Bunschoten C,Van Doorn PA.Mortality in Guillain-Barre syndrome[J].Neurology,2013,80(18):1650-1654.
[24] Prognosis T,Main Prognostic Indicators of Guillain-Barre Syndrome.A multicentre prospective study of 297 patients.The Italian Guillain-Barre Study Group[J].Brain,1996,119(Pt 6):2053-2061.
[25] Lawn ND,Wijdicks EF.Fatal Guillain-Barre syndrome[J].Neurology,1999,52(3):635-638.
[26] Cornblath DR,Mellits ED,Griffin JW,et al.Motor conduction studies in Guillain-Barre syndrome:description and prognostic value[J].Ann Neurol,1988,23(4):354-359.
[27] Chio A,Cocito D,Leone M,et al.Guillain-Barre syndrome:a prospective,population-based incidence and outcome survey[J].Neurology,2003,60(7):1146-1150.
[28] Van Koningsveld R,Steyerberg EW,Hughes RA,et al.A clinical prognostic scoring system for Guillain-Barre syndrome[J].Lancet Neurol,2007,6(7):589-594.
[29] Walgaard C,Lingsma HF,Ruts L,et al.Early recognition of poor prognosis in Guillain-Barre syndrome[J].Neurology,2011,76(11):968-975.
[30] Verma R,Chaudhari TS,Raut TP,et al.Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome(GBS)[J].J Neurol Sci,2013,335(1/2):105-111.
[31] Cheng BC,Chang WN,Chen JB,et al.Long-term prognosis for Guillain-Barre syndrome: Evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis[J].J Clin Apher,2003,18(4):175-180.
[32] Hiraga A,Mori M,Ogawara K,et al.Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome[J].J Neurol Neurosurg Psychiatry,2005,76(5):719-722.
[33] Kuwabara S,Mori M,Ogawara K,et al.Indicators of rapid clinical recovery in Guillain-Barre syndrome[J].J Neurol Neurosurg Psychiatry,2001,70(4):560-562.
[34] Hosokawa T,Nakajima H,Unoda K,et al.An electrophysiological classification associated with Guillain-Barr, syndrome outcomes[J].J Neurol,2014,261(10):1986-1993.
[35] Kuwabara S,Asahina M,Koga M,et al.Two patterns of clinical recovery in Guillain-Barre syndrome with IgG anti-GM1 antibody[J].Neurology,1998,51(6):1656-1660.
[36] Koga M,Yuki N,Hirata K,et al.Anti-GM1 antibody IgG subclass:a clinical recovery predictor in Guillain-Barre syndrome[J].Neurology,2003,60(9):1514-1518.
[37] Hadden RD,Karch H,Hartung HP,et al.Preceding infections,immune factors,and outcome in Guillain-Barre syndrome[J].Neurology,2001,56(6):758-765.
[38] Petzold A,Hinds N,Murray N,et al.CSF neurofilament levels: A potential prognostic marker in Guillain-Barre syndrome[J].Neurology,2006,67(6):1071-1073.
[39] Petzold A,Brettschneider J,Jin K,et al.CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barre syndrome[J].Muscle Nerve,2009,40(1):42-49.
[40] Notturno F,Caporale CM,De Lauretis A,et al.Glial fibrillary acidic protein: A marker of axonal Guillain-Barre syndrome and outcome[J].Muscle Nerve,2008,38(1):899-903.
[41] Strauss J,Aboab J,Rottmann M,et al.Plasma cortisol levels in Guillain-Barre syndrome[J].Crit Care Med,2009,37(8):2436-2440.
[42] Saifudheen K,Jose J,Gafoor VA,et al.Guillain-Barre syndrome and SIADH[J].Neurology,2011,76(8):701-704.
[43] Fokkink W-,Walgaard C,Kuitwaard KA,et al.Association of albumin levels with outcome in intravenous Immunoglobulin-Treated Guillain-Barre syndrome[J].JAMA Neurol,2017,74(2):189-196.